KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial.

Yu Wang, Qi-Fa Liu, De-Pei Wu, Zheng-Li Xu, Ting-Ting Han, Yu-Qian Sun, Fen Huang, Zhi-Ping Fan, Na Xu, Feng Chen, Ye Zhao, Yuan Kong, Xiao-Dong Mo, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang

BMC Med 22(1) 176

PMID38664766
PMCIDPMC11044329
DOI10.1186/s12916-024-03395-y
发表日期2024-04-25
入排依据:While the study meets many inclusion criteria (Phase III, randomized, human oncology, drug intervention, original result report), it is ineligible for the KM cohort because the primary efficacy endpoint is not a time-to-event measure. The only time-to-event endpoint reported (failure-free survival) appears to be a secondary endpoint, not the pre-specified primary or key secondary time-to-event endpoint required for this cohort.
摘要

摘要

BACKGROUND: There is an urgent unmet need for effective initial treatment for acute graft-versus-host disease (aGVHD) adding to the standard first-line therapy with corticosteroids after allogeneic haematopoietic stem cell transplantation (allo-HSCT). METHODS: We performed a multicentre, open-label, randomized, phase 3 study. Eligible patients (aged 15 years or older, had received allo-HSCT for a haematological malignancy, developed aGVHD, and received no previous therapies for aGVHD) were randomly assigned (1:1) to receive either 5 mg/m2 MTX on Days 1, 3, or 8 and then combined with corticosteroids or corticosteroids alone weekly. RESULTS: The primary endpoint was the overall response rate (ORR) on Day 10. A total of 157 patients were randomly assigned to receive either MTX plus corticosteroids (n = 78; MTX group) or corticosteroids alone (n = 79; control group). The Day 10 ORR was 97% for the MTX group and 81% for the control group (p = .005). Among patients with mild aGVHD, the Day 10 ORR was 100% for the MTX group and 86% for the control group (p = .001). The 1-year estimated failure-free survival was 69% for the MTX group and 41% for the control group (p = .002). There were no differences in treatment-related adverse events between the two groups. CONCLUSIONS: In conclusion, mini-dose MTX combined with corticosteroids can significantly improve the ORR in patients with aGVHD and is well tolerated, although it did not achieve the prespecified 20% improvement with the addition of MTX. TRIAL REGISTRATION: The trial was registered with clinicaltrials.gov (NCT04960644).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。